Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
about
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromesPlatelet glycoprotein IIb/IIIa receptor blockade in coronary artery diseaseOrbofiban: an orally active GPIIb/IIIa platelet receptor antagonistPlatelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarctionRole of abciximab in the treatment of coronary artery diseasePlatelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for RoxifibanThe therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.ABCIXIMAB: a new antiaggregant used in angioplasty.New antithrombotic drugs for systemic and local delivery for coronary artery disease.Thrombolytic drugs in acute myocardial infarction.Update on strategies to improve thrombolysis for acute myocardial infarction.Therapeutic potential of GP IIb/IIIa receptor antagonists in acute myocardial infarction.Facilitated thrombolysis: dethrombosis?Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction.Prevention of thrombosis and rethrombosis and enhancement of the thrombolytic actions of recombinant tissue-type plasminogen activator in the canine heart by DMP728, a glycoprotein IIb/IIIa antagonistAggregometry detects platelet hyperreactivity in healthy individualsGlycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Conversion from chronic to acute coronary heart disease syndromes. Role of platelets and platelet products.Successful Treatment of a Left Main Thrombus by Intracoronary Eptifibatide Infusion in a 36-Year-Old Patient.Inhibition of platelet aggregation as a surrogate marker.Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: results of ReoMI pilot study.New Antithrombotic Drugs of Coronary Artery Disease.Improving reperfusion after myocardial infarction.A novel peptide motif for platelet fibrinogen receptor recognition.
P2860
Q24202522-8BE6034B-A18B-4842-B8D8-1C58C4ED6617Q24202999-CBFF7524-40A4-46E2-B7D6-DCC5CF933920Q24235385-930D4128-438D-4219-BF80-58E5F6080C04Q24793321-C96F555D-0041-49BD-B963-3FA7A189D245Q28181764-2231A519-5D12-4C99-99EE-8850175F7992Q28191096-7FA1BB6D-A133-41D2-A94D-6CCEF55C5B66Q28200177-A40BB85C-1852-4DAB-A2E1-6F9375A87637Q28365831-1A8E2AB3-0974-4974-BEE3-6D4AA2A1E659Q33367036-F8C8671B-248F-41D4-A4B5-0443E246675EQ33497071-4F39D4B8-A315-4E61-A5A1-13EC56674D74Q33568892-FBBD823E-EBC4-4059-A2FB-ED16FD85E6B1Q33868351-297B0369-17C4-4D12-B358-AB9F39F8F34FQ34278839-7095873A-7B7C-4332-983E-765559D969EBQ34481832-54B0EBF6-0454-4886-82EC-E2F07464C58FQ34743945-ABA60876-3813-4ADC-8BF8-9EA696BADAD1Q34748832-0AA4CB56-121A-4618-BDAE-6EEAC5CF91C9Q34793710-9BFE256E-B920-400C-BCF9-EFCCA86B4AD7Q35126679-EC5B1416-8C9F-4FDF-9B81-15C475BDD6C1Q35139249-B30ADD5B-4932-4998-89D8-55DC23825E73Q35654672-78CC423F-0FA8-4547-BFC4-EAA8619AA5B1Q37490959-B2BB8EE1-ACEE-4486-AF02-3119F806B751Q41361493-E7551437-1D9F-4931-8EB5-A7BD853E00E7Q41702106-BC74AC8A-23C6-4390-A78F-6EEB9EC912C3Q41720782-02415F51-17FD-49A1-8547-E23A560B0568Q42765510-7A98A3F1-161D-45CE-B083-2A4A004BA1F1Q46560846-43E68E16-8746-4C96-B576-C26AFBEF7823
P2860
Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study.
description
1993 nî lūn-bûn
@nan
1993 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@ast
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@en
type
label
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@ast
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@en
prefLabel
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@ast
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@en
P2093
P50
P1476
Profound inhibition of platele ...... farction (TAMI) 8 Pilot Study.
@en
P2093
Aguirre FV
Kereiakes D
Kleiman NS
Schaible T
P304
P356
10.1016/0735-1097(93)90041-X
P407
P577
1993-08-01T00:00:00Z